MII IG Kerndatensatz-Modul Molekulares Tumorboard
2027.0.0-ballot.1 - Germany

This page is part of the MII Implementation Guide Molecular Tumor Board (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

Example RequestGroup: mii-exa-mtb-therapieempfehlung-kombinationstherapie

English

Profile: MII PR MTB Therapieempfehlung Kombinationstherapie version: 2027.0.0-ballot.1

MII EX MTB Empfehlung Priorität: 1

MII EX MTB Empfehlung Publikation: https://doi.org/10.1002/gcc.23222

MII EX MTB Empfehlung Evidenzgraduierung: Case study or single unusual responder indicates the biomarker is associated with response to the drug in the same tumor type.

status: Active

intent: Proposal

subject: Maxim Muster (no stated gender), DoB Unknown

authoredOn: 2024-01-01

action

title: Therapieempfehlung für Dabrafenib

resource: MedicationRequest: status = active; intent = option; medication[x] = Dabrafenib; authoredOn = 2024-01-01

action

title: Therapieempfehlung für Trametinib

resource: MedicationRequest: status = active; intent = option; medication[x] = Trametinib; authoredOn = 2024-01-01